Showing 1 - 20 results out of 9,710 with the query:
*
with facets:
Host Organism:recombinant X
Anti-SSEA-4-PE-Vio770 antibody
SSEA-4 human
Miltenyi Biotec Go To Vendor
130-105-051
(Miltenyi Biotec Cat# 130-105-051, RRID:AB_2631260)
monoclonal antibody
REA101
recombinant
Entered market 2014-07-01; Target Distribution ES and iPS cells, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Human anti-RTF scFv antibody
RTF molecule
F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran
B2012
(F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran Cat# B2012, RRID:AB_2636849)
monoclonal antibody
recombinant
It is a novel promising human antibody for use in immunotherapy of prostate cancer; Not raised in a species. It is produced from a scFv library by phage display technology. The library was originated from human immunoglobulin genes using antibody engineering system
Anti-MUC18 scFv antibody
MUC 18 Molecule (amino acids LADGNPPPHF)
F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran
IR94
(F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran Cat# IR94, RRID:AB_2636864)
monoclonal antibody
recombinant
The antibody is a novel scFv with anti-metastatic and anti-invasion effects on breast cancer cells; validation is described in the paper cited Appl Biochem Biotechnol. 2017 Jan;181(1):379-390
Anti-IL25 receptor scFvI antibody
IL25 receptor molecule (amino acids 102-118 of IL25 receptor)
F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran
IL25R102
(F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran Cat# IL25R102, RRID:AB_2636865)
monoclonal antibody
recombinant
Validation described in this paper International immunopharmacology 2014; 23(2): 624-32
Anti-IL25 receptor scFvII antibody
IL25 receptor molecule (amino acids 213-243 of IL25 receptor)
F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran
IL25R213
(F. Nejatollahi. Shiraz University of Medical Sciences, Shiraz, Iran Cat# IL25R213, RRID:AB_2636866)
monoclonal antibody
recombinant
a new scFv with anti-proliferative and apoptotic effects on breast cancer cells; validation described in International immunopharmacology 2014; 23(2): 624-32
CD158e1/e2 antibody, human (clone: REA168) ­PerCP ­Vio700
CD158e1/e2 (KIR3DS1/L1) human
Miltenyi Biotec
130-­104-­837
(Miltenyi Biotec Cat# 130-­104-­837, RRID:AB_2651041)
unknown
REA168
recombinant
discontinued 11/2018
Anti-ADAM15-PE antibody
ADAM15 human
Miltenyi Biotec Go To Vendor
130-109-906
(Miltenyi Biotec Cat# 130-109-906, RRID:AB_2651193)
monoclonal antibody
REA650
recombinant
Entered market 2016-03-01; Target Distribution smooth muscle, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAM15-PE antibody
ADAM15 human
Miltenyi Biotec Go To Vendor
130-109-864
(Miltenyi Biotec Cat# 130-109-864, RRID:AB_2651194)
monoclonal antibody
REA650
recombinant
Entered market 2016-03-01; Target Distribution smooth muscle, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAM15-APC antibody
ADAM15 human
Miltenyi Biotec Go To Vendor
130-109-907
(Miltenyi Biotec Cat# 130-109-907, RRID:AB_2651195)
monoclonal antibody
REA650
recombinant
Entered market 2016-03-01; Target Distribution smooth muscle, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAM15-APC antibody
ADAM15 human
Miltenyi Biotec Go To Vendor
130-109-865
(Miltenyi Biotec Cat# 130-109-865, RRID:AB_2651196)
monoclonal antibody
REA650
recombinant
Entered market 2016-03-01; Target Distribution smooth muscle, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAMTS13-PE antibody
ADAMTS13 human
Miltenyi Biotec Go To Vendor
130-109-315
(Miltenyi Biotec Cat# 130-109-315, RRID:AB_2651197)
monoclonal antibody
REA593
recombinant
Entered market 2015-12-01; Target Distribution liver; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAMTS13-PE antibody
ADAMTS13 human
Miltenyi Biotec Go To Vendor
130-109-237
(Miltenyi Biotec Cat# 130-109-237, RRID:AB_2651198)
monoclonal antibody
REA593
recombinant
Entered market 2015-12-01; Target Distribution liver; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAMTS13-APC antibody
ADAMTS13 human
Miltenyi Biotec Go To Vendor
130-109-316
(Miltenyi Biotec Cat# 130-109-316, RRID:AB_2651199)
monoclonal antibody
REA593
recombinant
Entered market 2015-12-01; Target Distribution liver; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-ADAMTS13-APC antibody
ADAMTS13 human
Miltenyi Biotec Go To Vendor
130-109-238
(Miltenyi Biotec Cat# 130-109-238, RRID:AB_2651200)
monoclonal antibody
REA593
recombinant
Entered market 2015-12-01; Target Distribution liver; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-Aiolos-PE antibody
Aiolos mouse
Miltenyi Biotec Go To Vendor
130-110-341
(Miltenyi Biotec Cat# 130-110-341, RRID:AB_2651201)
monoclonal antibody
REA655
recombinant
Entered market 2016-05-01; Target Distribution spleen, B cells, thymocytes, bone marrow; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL
Anti-Aiolos-PE antibody
Aiolos mouse
Miltenyi Biotec Go To Vendor
130-110-240
(Miltenyi Biotec Cat# 130-110-240, RRID:AB_2651202)
monoclonal antibody
REA655
recombinant
Entered market 2016-05-01; Target Distribution spleen, B cells, thymocytes, bone marrow; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL
Anti-Aiolos-APC antibody
Aiolos mouse
Miltenyi Biotec Go To Vendor
130-110-342
(Miltenyi Biotec Cat# 130-110-342, RRID:AB_2651203)
monoclonal antibody
REA655
recombinant
Entered market 2016-05-01; Target Distribution spleen, B cells, thymocytes, bone marrow; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL
Anti-Aiolos-APC antibody
Aiolos mouse
Miltenyi Biotec Go To Vendor
130-110-241
(Miltenyi Biotec Cat# 130-110-241, RRID:AB_2651204)
monoclonal antibody
REA655
recombinant
Entered market 2016-05-01; Target Distribution spleen, B cells, thymocytes, bone marrow; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL
Anti-AKT Pan (PKB)-PE antibody
AKT Pan (PKB) human, mouse, rat
Miltenyi Biotec Go To Vendor
130-110-365
(Miltenyi Biotec Cat# 130-110-365, RRID:AB_2651205)
monoclonal antibody
REA676
recombinant
Entered market 2016-05-01; Target Distribution ubiquitous; target type Non-CD markers, REAfinity Antibodies, Cell signaling antibodies; tested applications MACS Flow Cytometry; quantity:
Anti-AKT Pan (PKB)-PE antibody
AKT Pan (PKB) human, mouse, rat
Miltenyi Biotec Go To Vendor
130-110-264
(Miltenyi Biotec Cat# 130-110-264, RRID:AB_2651206)
monoclonal antibody
REA676
recombinant
Entered market 2016-05-01; Target Distribution ubiquitous; target type Non-CD markers, REAfinity Antibodies, Cell signaling antibodies; tested applications MACS Flow Cytometry; quantity: